Lung tracker considers ASX tilt

As printed in the The Age
Friday 22nd May 2020
Page 27 | Section: BUSINESS

 

ASX medtech hopeful 4D Medical has joined a pack of Australian start-ups hoping to get a green light from the US Food and Drug Administration (FDA) to market its product in the coronavirus era.

4D Medical has developed a software platform that analyses chest X-rays to help doctors better track respiratory impairments. TheXV Technology uses an algorithm to generate reports for hospital staff so they can better plan treatments for patients in respiratory distress.

While the product doesn’t replace tests for COVID-19, the hope is that the software could help hospitals determine treatment paths faster and track patient progress in the pandemic era.

4D Medical confirmed yesterday the FDA granted it permission to market the product in the US. The startup is still a private company but management is eyeing an ASX listing in the months to come.